Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Sorry Donrun

<< Previous

Bullboard Posts

Next >>

Comment by Red~Oneon Feb 11, 2022 10:52pm

104 Views

Post# 34422661

RE:RE:RE:RE:RE:RE:Sorry Donrun

Sorry I missed something...: you said " I didn't know there were FDA, EMEA, PMDA and MHRA approved NO prodrugs out there,?" No not yet but close... I didn't mean to imply that they were approved, mostly in hospitals and labs in Phase 2. don't be putting words in my mouth, that's a cheap way to discuss things , that ain't kosher....bom bom or pacman?

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale